Pluto Bioinformatics

GSE99116: Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Bulk RNA sequencing

We compared three CDK4/6 inhibitors that have recently emerged as highly promising agents for advanced breast cancers by performing transcriptional profiling (mRNA-Seq) on a panel of seven breast cancer cell lines following 6 or 24 hours of drug exposure at concentrations ranging from 0.3 to 3.0 uM. SOURCE: Peter Sorger (peter_sorger@hms.harvard.edu) - Sorger lab Harvard Medical School